Mobile

An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and Ra...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-017032-41

An Open-Label, Randomized Study Evaluating a Switch from a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors plus any Third Agent to either a Regimen of Atazanavir/Ritonavir Once Daily and Raltegravir Twice Daily or to a Regimen of Atazanavir/Ritonavir Once Daily and Tenofovir/Emtricitabine Once Daily in Virologically Suppressed HIV-1 Infected Subjects With Safety and/or Tolerability Issues on their Present Treatment Regimen (the HARNESS study)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to estimate the proportion of subjects with HIV 1 RNA < 40 c/mL through 24 weeks, following a switch due to treatment related safety and/or tolerability issues, from a regimen consisting of 2 NRTI + any 3rd agent, to a regimen consisting of ATV/RTVHS 300/100mg QD + RAL 400 mg BID

Critère d'inclusion

  • HIV-1 infected subjects who are virologically suppressed on a regimen of 2 NRTIs plus any 3rd agent, but experience safety and/or tolerability issues to this regimen

Liens